NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

I mean you all get this, right? Dr. Linda Liau stated five years ago it seemed like everyone is living longer. So what we are really comparing is DCVax EARLY with DCVax late. Four years later she essentially stated DCVax-l only seemed to work well at improving long term survival if it was given EARLY.

Translation? Crossover from either arm had no discernible impact. One could, of course, see this from a blinded perspective. (Note: This trial rarely used recurrent surgery with crossover)

That takes care of issue number 1.

If crossover is no longer an issue, that leaves pseudoprogression. That was “re-reviewed” in November 2018, again, according to Dr. Liau. By 2019, Dr. Liau was still confirming long term survivors are mostly patients without any recurrence.

That takes care of issue number 2.

flipper44,

Thank you! That is also my opinion. I think that pseudoprogression was never a big big issue!

Note: with all the information available you can figure out the most conservative mPFS of the treatment group of the last 108 patients.